Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.

Sectors
Healthcare
Life Sciences
First Invested
2011
Public/PIPES
Company Status
IPO/Acquired
NASDAQ: ITMN
Acquired by Roche Holding AG
Website
InterMune